These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 9508789)
21. The potentiation of human C1-inhibitor by dextran sulphate is transient in vivo: studies in a rat model. Bos IG; van Mierlo GJ; Bleeker WK; Rigter GM; te Velthuis H; Dickneite G; Hack CE Int Immunopharmacol; 2001 Aug; 1(8):1583-95. PubMed ID: 11515821 [TBL] [Abstract][Full Text] [Related]
22. C-1-inhibitor binding monoclonal immunoglobins in three patients with acquired angioneurotic edema. Chevailler A; Arlaud G; Ponard D; Pernollet M; Carrère F; Renier G; Drouet M; Hurez D; Gardais J J Allergy Clin Immunol; 1996 Apr; 97(4):998-1008. PubMed ID: 8655897 [TBL] [Abstract][Full Text] [Related]
23. Interactions of plasma kallikrein and C1-s with normal and dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema: analytic gel studies. Donaldson VH; Wagner CJ; Tsuei B; Kindness G; Bing DH; Harrison RA; Rosen FS Blood; 1987 Apr; 69(4):1096-101. PubMed ID: 3493816 [TBL] [Abstract][Full Text] [Related]
24. Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement. Peitsch MC; Kovacsovics TJ; Tschopp J; Isliker H J Immunol; 1987 Mar; 138(6):1871-6. PubMed ID: 3029223 [TBL] [Abstract][Full Text] [Related]
26. Hereditary and acquired deficiencies of C1 inhibitor. Davis AE Immunodefic Rev; 1989; 1(3):207-26. PubMed ID: 2698641 [TBL] [Abstract][Full Text] [Related]
27. Modulation of the proteolytic activity of the complement protease C1s by polyanions: implications for polyanion-mediated acceleration of interaction between C1s and SERPING1. Murray-Rust TA; Kerr FK; Thomas AR; Wu T; Yongqing T; Ong PC; Quinsey NS; Whisstock JC; Wagenaar-Bos IC; Freeman C; Pike RN Biochem J; 2009 Aug; 422(2):295-303. PubMed ID: 19522701 [TBL] [Abstract][Full Text] [Related]
28. Acquired angioedema: Autoantibody associations and C1q utility as a diagnostic tool. Breitbart SI; Bielory L Allergy Asthma Proc; 2010; 31(5):428-34. PubMed ID: 20929611 [TBL] [Abstract][Full Text] [Related]
29. Primary structure of the reactive site of human C1-inhibitor. Salvesen GS; Catanese JJ; Kress LF; Travis J J Biol Chem; 1985 Feb; 260(4):2432-6. PubMed ID: 3919001 [TBL] [Abstract][Full Text] [Related]
30. The Crystal Structure of the Michaelis-Menten Complex of C1 Esterase Inhibitor and C1s Reveals Novel Insights into Complement Regulation. Garrigues RJ; Garrison MP; Garcia BL J Immunol; 2024 Sep; 213(5):718-729. PubMed ID: 38995166 [TBL] [Abstract][Full Text] [Related]
31. Acquired C1 inhibitor deficiency as a result of an autoantibody to the reactive center region of C1 inhibitor. Mandle R; Baron C; Roux E; Sundel R; Gelfand J; Aulak K; Davis AE; Rosen FS; Bing DH J Immunol; 1994 May; 152(9):4680-5. PubMed ID: 7512602 [TBL] [Abstract][Full Text] [Related]
32. Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Cicardi M; Zingale LC; Pappalardo E; Folcioni A; Agostoni A Medicine (Baltimore); 2003 Jul; 82(4):274-81. PubMed ID: 12861105 [TBL] [Abstract][Full Text] [Related]
33. Autoantibody-mediated acquired deficiency of C1 inhibitor. Alsenz J; Bork K; Loos M N Engl J Med; 1987 May; 316(22):1360-6. PubMed ID: 3494945 [TBL] [Abstract][Full Text] [Related]
34. Changes in protein conformation and stability accompany complex formation between human C1 inhibitor and C1-s. Lennick M; Brew SA; Ingham KC Biochemistry; 1985 May; 24(10):2561-8. PubMed ID: 3874650 [TBL] [Abstract][Full Text] [Related]
36. The Janus faces of acquired angioedema: C1-inhibitor deficiency, lymphoproliferation and autoimmunity. Wu MA; Castelli R Clin Chem Lab Med; 2016 Feb; 54(2):207-14. PubMed ID: 26068904 [TBL] [Abstract][Full Text] [Related]
37. The Levels of the Lectin Pathway Serine Protease MASP-1 and Its Complex Formation with C1 Inhibitor Are Linked to the Severity of Hereditary Angioedema. Hansen CB; Csuka D; Munthe-Fog L; Varga L; Farkas H; Hansen KM; Koch C; Skjødt K; Garred P; Skjoedt MO J Immunol; 2015 Oct; 195(8):3596-604. PubMed ID: 26371246 [TBL] [Abstract][Full Text] [Related]
38. Substrate properties of C1 inhibitor Ma (alanine 434----glutamic acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor/substrate status. Skriver K; Wikoff WR; Patston PA; Tausk F; Schapira M; Kaplan AP; Bock SC J Biol Chem; 1991 May; 266(14):9216-21. PubMed ID: 2026621 [TBL] [Abstract][Full Text] [Related]
39. Antibody-independent activation of C1. I. Differences in the mechanism of C1 activation by nonimmune activators and by immune complexes: C1r-independent activation of C1s by cardiolipin vesicles. Kovacsovics TJ; Peitsch MC; Kress A; Isliker H J Immunol; 1987 Mar; 138(6):1864-70. PubMed ID: 3029222 [TBL] [Abstract][Full Text] [Related]
40. Citrullination of C1-inhibitor as a mechanism of impaired complement regulation in rheumatoid arthritis. Martin M; Nilsson SC; Eikrem D; Fromell K; Scavenius C; Vogt LM; Bielecka E; Potempa J; Enghild JJ; Nilsson B; Ekdahl KN; Kapetanovic MC; Blom AM Front Immunol; 2023; 14():1203506. PubMed ID: 37426666 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]